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Abstract 
Siblings of patients with Crohn’s disease (CD) have elevated risk of developing CD and display aspects of 
disease phenotype, including faecal dysbiosis. In our recent article we have used 16S rRNA gene targeted 
high-throughput sequencing to comprehensively characterise the mucosal microbiota in healthy siblings 
of CD patients, and determine the influence of genotypic and phenotypic factors on the gut microbiota 
(dysbiosis). We have demonstrated that the core microbiota of both patients with CD and healthy 
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siblings is significantly less diverse than controls. Faecalibacterium prausnitzii contributed most to core 
metacommunity dissimilarity between both patients and controls and between siblings and controls. 
Phenotype/genotype markers of CD risk significantly influenced microbiota variation between and within 
groups, of which genotype had the largest effect. Individuals with elevated CD-risk display mucosal 
dysbiosis characterised by reduced diversity of core microbiota and lower abundance of F. prausnitzii. 
The presence of this dysbiosis in healthy people at-risk of CD implicates microbiological processes in CD 
pathogenesis. 
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In contrast to skin, lung or eye, where barrier function is prioritised and the range of substances targeted 
for absorption are limited, the surface of the gut has uniquely evolved to actively interact with a wide 
variety of ingested constituents of the host’s environment. Why the regulation of this intricate interface 
between humans and their environment degenerates in inflammatory bowel disease (IBD) is unclear. 
However, in some genetically predisposed individuals an abnormal immune reaction to gut microbes 
develops and results in chronic intestinal inflammation. Traditionally, two main clinical entities have 
been described: Crohn’s disease (CD) and ulcerative colitis. However, genetic and microbiome studies 
have challenged this dogma; for example some studies support a difference between small intestinal-
restricted and colonic-involving CD.[1, 2] 
A genetic predisposition to IBD is fundamental and relatives of patients are at enhanced risk of 
developing IBD themselves.[3, 4] The interaction between the gut microbiota and the gut immune 
system is pivotal in IBD pathogenesis[5] and in patients with IBD abnormalities can be demonstrated in 
both the gut immune system and the gut microbiota (dysbiosis) as well as alterations in intestinal 
permeability and increased concentrations of neutrophil-derived calprotectin in faeces.[6] However, 
whether dysbiosis has a role in disease pathogenesis or is merely consequent to inflammation cannot be 
determined by examining only individuals with established IBD. For example, increased faecal γ-
proteobacteria have been widely described in CD[5, 7] particularly increased in Escherichia coli,[8] and 
putative mechanisms by which E. coli may contribute to CD pathogenesis include the capacity to adhere 
to and invade the intestinal mucosa,[9, 10] as well as the persistence of these bacteria in epithelial cells 
and macrophages.[11] However, there are also potential mechanisms by which E. coli may be increased 
opportunistically as a consequence of CD, such as the increased activity of nitric oxide synthases 
associated with inflammation,[12] which could favour the survival of these nitrate-reducing bacteria, or 
increased intestinal luminal pH secondary to a reduction in faecal butyrate producers frequently 
reported in CD – potentially favouring the survival of organisms that are inhibited at acidic pH such as E. 
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coli.[13] Moreover, there is also evidence that the abundance of γ-proteobacteria may be affected by 
drugs such as immunosuppressant and 5-ASA drugs used to treat CD.[14] There has therefore been an 
ongoing conundrum as to whether the dysbiosis in IBD patients is a feature of  pathogenesis or whether 
it occurs after disease onset as a result of established inflammation. The temporal relationship between 
dysbiosis and disease onset is not easily examined in humans, however these factors may be more 
readily manipulated in animal models. There is a strong implication from animal models of IBD that the 
microbiota are a key part of disease pathogenesis given that in several animal models of gut 
inflammation, animals kept in germ-free conditions do not develop disease.[15-18] Genotype-
environment interactions may also be examined in animal models, such as that described between 
Atg16L1 and murine norovirus in a mouse model of CD.[19] However, extrapolation from animal data to 
human disease should be approached with caution. Studying individuals before they develop CD, or 
individuals who share genetic and environmental exposures that predispose to IBD, but in whom the 
cumulative effect of these triggers is, as yet, insufficient to produce the full-blown disease phenotype, 
i.e. healthy relatives of IBD patients, provide a window into pathogenic pathways in the absence of the 
obfuscating influence of established, chronic CD.   
In our recent publication “Siblings of patients with Crohn’s disease exhibit biologically relevant dysbiosis 
in mucosal microbial metacommunities”[20] we used 16S rRNA gene targeted high-throughput 
sequencing to test the hypothesis that dysbiosis exists in the mucosal microbiota of healthy siblings of 
CD patients, and is therefore not merely a consequence of established disease. In addition, we examined 
the influence of genotypic and phenotypic factors, on that dysbiosis. Twenty-one patients with quiescent 
CD and 17 of their healthy siblings were recruited via gastroenterology outpatient clinics, in addition to 
19 unrelated healthy controls. Participants at the peak age when CD is diagnosed (16-35 years),[21] were 
specifically targeted in order that data from this study is most relevant to the population in which any 
future pre-disease screening programme is the most viable. In addition, enrolling only young relatives of 
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CD patients increases the possibility of including individuals who will go on to develop CD. Healthy but 
genetically predisposed relatives may manifest biomarkers that reflect genetic risk or environmental 
exposures and crucially, may reveal their cumulative and combined effects. In addition, an accurate 
description of the ‘at risk’ state in siblings and offspring of CD patients raises the potential to predict and 
prevent disease. Moreover, longitudinal surveys in families who are enriched for both genetic and 
environmental risk factors provide a cohort with greater incidence of CD. However, the analysis of CD 
pathogenesis in healthy siblings is not completely straightforward. First, the degree of genetic 
relatedness of full-siblings is on average around 50% but detailed analysis of sibling genomes reveals that 
their similarity may vary between 37 to 62%.[22] Secondly, expression of risk phenotypes may depend 
on environmental exposures that may vary between family members; for example aspirin may induce 
increased intestinal permeability.[23] Finally, one of the advantages of family studies (the capacity to 
examine genotype-environment interactions) is also a limitation in that it may not be possible to 
determine whether a phenotype that is shared between siblings is shared because of genotype (e.g. 
genetic determination of gut microbiota) or shared environment (e.g. maternal microbial inoculum 
determining neonatal gut microbiota). Such questions may be addressed using twin cohorts. Despite 
these limitations, studies of healthy, at-risk relatives of patients with CD may uniquely contribute to the 
illumination of pathogenic pathways that are not easily discernible in studying patients with established 
disease. 
We showed that core microbiota of both CD patients and healthy siblings were significantly less diverse 
compared with healthy unrelated controls. This finding confirms that dysbiosis is not merely a 
consequence of intestinal inflammation but is also present in at-risk, healthy individuals, clearly 
implicating the microbiota in CD pathogenesis. The significance of reduced microbial diversity is not fully 
understood but it is interesting to speculate on because this is a feature of the dysbiosis in a variety of 
diseased states including obesity,[24, 25] colorectal cancer,[26] eczema,[27] and in addition has been 
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linked with smoking.[28] Perhaps lower diversity is associated with incomplete occupation of ecological 
niches resulting in reduced resistance to colonisation by more pro-inflammatory species; alternatively a 
more restricted gut metagenome may contain a lower array of microbial genes that results in the loss of 
key functions. Currently it is not clear whether reduced diversity in itself has a specific functional 
consequence or if it functions as a barometer for the overall health of the gut microbiota. 
Using metacommunity profiling we also showed that the sibling core microbial composition is more 
similar to their CD affected siblings than to matched healthy controls, figure 1. Moreover, reduced 
Faecalibacterium prausnitzii contributed most to core metacommunity dissimilarity both between 
siblings and controls, and between patients and controls. As a proportion of core species F. prausnitzii 
had a higher relative abundance in healthy controls (30.9%) than either patients with CD (22.4%) or 
siblings (24.2%). Interestingly, we had also previously demonstrated a similar finding in luminal samples 
from the same cohort (published separately): siblings had significantly lower concentrations of several 
Firmicute groups including Clostridia cluster IV, Roseburia spp. and F prausnitzii which was lower in 
siblings (median 9.27, IQR 8.12-9.78 log10 copies/g) compared with controls (median 9.59, IQR 9.34-10.14 
log10 copies/g, p=0.048) as well as between patients (median 6.88, IQR 5.03-9.35 log10 copies/g) 
compared with controls (p=0.006), figure 2.[29] Thus, the finding of sibling dysbiosis including reduced 
abundance of F. prausnitzii is robust, having been demonstrated in analyses using different techniques 
(454 pyrosequencing and qPCR), and in both mucosa-associated and faecal microbiota  
There has been intense speculation regarding the role of F. prausnitzii in CD pathogenesis as it is the only 
microbial factor shown to be predictive of the natural history of CD[30] and of the response to 
treatment.[31] It may be speculated that loss of F. prausnitzii could result in the loss of key functions that 
contribute to gut health, for example the production of short-chain fatty acids, in particular butyrate, 
[32] and NFκB-mediated effects.[33] However, we would be cautious in constructing pathogenic 
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hypotheses based on the functions of this particular species, rather interpreting these data as implicating 
that loss of F. prausnitzii is a sensitive indicator of a broader change in the gut microbiota. Furthermore, 
data is emerging demonstrating increases in F. prausnitzii in new onset paediatric Crohn’s disease, 
indicating that the role this species plays in pathogenesis is complex.[34] Interestingly, increased E. coli 
contributed to the dissimilarity between patients and healthy controls but not to the dissimilarity 
between siblings and healthy controls. Thus it may be that the CD dysbiosis comprises microbial factors 
that contribute to pathogenesis (as exemplified by lower F. prausnitzii), overlaid with microbial 
alterations that are consequent to inflammation (as exemplified by higher abundance of E. coli). 
Alternatively, the sibling dysbiosis may represent an incomplete version of the full CD dysbiosis, which is 
insufficient to lead to full-blown CD. Only longitudinal studies can answer this question. 
Genotype contributes to CD pathogenesis[35] and in addition the composition of the gut microbiota is 
partly determined by genotype.[36] In our study we demonstrated that genotype relative risk (a 
composite score of genotypic risk across 72 loci associated with CD) was the most significant factor in 
explaining variance between the three cohorts, (patients, healthy siblings and healthy, unrelated 
controls) and also within each cohort. There is an evolutionary advantage to be accrued through host 
genetic influence over the colonisation by commensals in order to maximize host fitness. Furthermore, 
microbiota differ markedly from one host habitat to another, such as skin compared with gut,[37] and 
this indicates that there are selection pressures, potentially under host control, that determine the 
differential survival of bacteria in these sites. It would therefore be surprising if the capacity to influence 
host microbiota had failed to evolve within the human genome. If the host can shape the microbiota, it 
therefore follows that due to natural variation, in some individuals a suboptimal genotype will produce a 
less well-adapted phenotype, and furthermore may even result in disease. Recent data in animal models 
supports the role for the gut immune system in shaping the microbiota and suggests that this effect may 
be at least in part dependent on a pathway involving both polyreactive and bacteria-specific secretory 
 8 
 
IgA,[38] as well as mediated through gut epithelial cells and Hopx+ cell-derived miRNAs, which enter 
bacteria and regulate bacterial gene expression and growth, in turn affecting the microbiota composition 
and susceptibility to colitis.[39] Furthermore specific SNPs have been associated with gut microbiota 
composition in a cohort of healthy relatives.[36]  
We have shown that perturbations in the mucosal gut microbiota occur not only in individuals with 
Crohn’s disease but also in otherwise healthy individuals at elevated risk of Crohn’s disease, thus 
dysbiosis is not merely a consequence of inflammation. However, studies of paediatric IBD highlight 
paradoxical increases in species such as F. prausnitzii[34, 40] that are widely reported to be reduced in 
adults with IBD. Whilst this finding might suggest that alternative pathogenic pathways exist in paediatric 
IBD, it might also indicate that gut microbiota composition may evolve during pathogenesis. Rather than 
focussing on the microbial composition at the point when the individual develops the disease, it may be 
that the influence of the gut microbiota occurs long before disease onset. It may be speculated that 
there are critical periods during immune development when dysbiosis may exert its influence. The 
evidence for the importance of the early childhood period comes from several sources: studies of human 
migration from areas of low prevalence to high prevalence and vice versa indicate that in some 
populations IBD risk is associated with the area of birth,[41] implicating events in the perinatal or early 
childhood period in IBD pathogenesis. Many of the epidemiological associations with IBD link to early 
childhood, including breastfeeding, tonsillectomy, childhood vaccinations, childhood infections, [42] 
birth rank[43] and birth in hospital.[44] In conjunction, several of these factors have been shown to 
influence the gut microbiota[45], and the acquisition of the gut microbiota in humans appears to occur 
predominantly over the first two years of life.[46] In animal models gut immune maturation is influenced 
by the timing of introduction of gut microbiota,[47] implying that early microbial exposure may have the 
capacity to condition immune responses in the long-term. Moreover, other animal studies have 
implicated even pre-natal effects of the maternal microbiota on the developing immune system of the 
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foetus/ neonate. Such influences may be effected through factors including microbial molecular transfer 
mediated by maternal immunoglobulins transmitted both trans-placentally and through lactation.[48] 
Defining the interrelated processes of human immune development and microbial acquisition may have 
a significant impact on our understanding of the pathogenesis of IBD. 
Given the factors discussed above, it may be hypothesised that environmental factors impact on the 
acquisition of the gut microbiota during the prenatal, neonatal or early childhood period, which in turn 
creates a persistent inflammatory immune tone, thus laying the foundations for future IBD risk. Defining 
the relationship between microbial acquisition, immune phenotype and IBD risk requires longitudinal 
studies and the results of ongoing studies including the MECONIUMstudy  (Exploring MEChanisms Of 
disease traNsmisson In Utero through the Microbiome; a study comparing the bacterial profiles of 
pregnant women with and without IBD with their new-born babies and in addition assessing the 
influence of infant feeding practices and antibiotic use early in life on microbiota acquisition) and the 
GEM project (Genetics, Environment and Microbiota Project: A longitudinal study of relatives of patients 
with Crohn’s disease)[36] are eagerly awaited. 
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Figure 1. Dendrogram showing the microbial community dissimilarity between the three groups: The 
composition of the whole microbiota as determined by Bray-Curtis index, is more similar between 
patients and their healthy siblings than between healthy siblings and healthy controls, and this pattern is 
driven by similarity in the core microbiota between patients and siblings rather than the rare microbiota. 
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Figure 2. Concentrations of different Firmicute populations in faecal samples were significantly lower in 
patients (n=22) and siblings, (n=21) compared with controls, (n=25). 
